Oral Answers to Questions

Debate between Marion Fellows and Matt Hancock

Tuesday 29th October 2019 Commons Chamber

[Marion Fellows (Motherwell and Wishaw) (SNP)]

18. What progress he has made on increasing access to drugs to treat cystic fibrosis.

[The Secretary of State for Health and Social Care (Matt Hancock)]

I am delighted that a deal has been agreed to provide Orkambi and other cystic fibrosis drugs on the NHS. This deal is great value for the NHS and backed by the National Institute for Health and Care Excellence, but crucially it will improve thousands of lives. My heartfelt thanks go out to many campaigners from right across the House who have pushed this agenda but especially to the Cystic Fibrosis Trust and the patients who, along with their families, have bravely campaigned against this devastating disease. I am thrilled that we can make this progress.

--- Later in debate ---

[Matt Hancock]

Absolutely. I pay tribute to the hon. Lady, who raised that case with me last night and gave me advance warning that she would raise it in the House today. I shall be happy to ensure that the relevant member of the team meets her with her constituent, if appropriate, so that we can get to the bottom of this.

[Marion Fellows (Motherwell and Wishaw) (SNP)]

I want to associate myself with the thanks to all the campaigners who worked so hard to ensure that these drugs would be available in England as well as Scotland. I never doubted that my Government would press and press, and I am delighted that the Secretary of State’s Government have followed suit. However, there are still great Brexit uncertainties. Given that people fought for so long, what reassurances can the Secretary of State give those who will obtain these life-saving drugs that they will be possible, affordable and sustainable?

[Matt Hancock]

The agreement that the hon. Lady’s Government—the UK Government—reached with Vertex means that this drug will be available in Wales and Northern Ireland as well. It is true that Scotland chose to go it alone and as a result has not received such good value for money, but what really matters is that the drug is now available throughout the United Kingdom.

Oral Answers to Questions

Debate between Marion Fellows and Matt Hancock

Tuesday 18th June 2019 Commons Chamber

[Marion Fellows (Motherwell and Wishaw) (SNP)]

Regardless of which type of Brexit we face this autumn, bureaucracy, customs charges and stockpiling costs will inevitably drive up the price of imported drugs and medical devices. Will the Secretary of State undertake to provide additional funds for NHS England and the devolved nations to cover those Brexit-induced costs and to avoid cuts in clinical services?

[Matt Hancock]

Additional funds have already been provided to ensure that medicines are available throughout the country, whatever the Brexit scenario.